Apitolisib
- Generic Name
- Apitolisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O3S
- CAS Number
- 1032754-93-0
- Unique Ingredient Identifier
- 1C854K1MIJ
- Background
Apitolisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, and Endometrial Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT01485861
- Locations
- 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
🇨🇿Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath